参考文献/References:
[1]冷晓宁,贾静,张伟华.β肾上腺素受体阻滞剂的研究进展[J].心血管病学进展,2011,32(4):569-572.
[2]Ahmad AA, Yasir AB,Ahmad HA,et al.Comparison of the effects of metoprolol and bisoprolol on lipid and glucose profiles in cardiovascular patients[J].Current Drug Safety, 2019,14(1):27-30.
[3]刘立伟,陈国良,刘红.口服美托洛尔引起血脂紊乱和β2肾上腺素受体基因多态性关系的研究[J].中国新药杂志,2010,19(18):1661-1665.
[4]黎镇赐.β-受体阻滞剂常见不良反应及处理对策[J].中华高血压杂志,2012,5:419-420.
[5]Angelo MC,Giuseppe A,Matteo C,et al.Antihypertensive treatment with beta-blockers in the metabolic syndrome: a review[J].Curr Diabetes Rev, 2010,6(4),215-221.
[6]Ali GO,Serpil E,Ugur B,et al.Effects of carvedilol compared to nebivolol on insulin resistance and lipid profile in patients with essential hypertension[J].J Cardiovasc Pharmacol Ther,2017,22(1): 65-70.
[7]Bharati SM,Singh N.Effect of losartan and atenolol on insulin sensitivity in nondiabetic hypertensive patients[J].J Pharmacol Pharmacother,2016,7(2):80-86.
[8]Sparks JD,Sparks CE,Adeli K.Selective hepatic insulin resistance, VLDL overproduction, and hypertriglyceridemia[J].Arterioscler Thromb Vasc Biol,2012,32(9):2104-2112.
[9] Cheng Z.FoxO1:mute for a tuned metabolism？[J].Trends Endocrinol Metab,2015,26(8):402-403.
[10]Ting Z,Dae HK,Xiang WX,et al.FoxO1 plays an important role in regulating beta-cell compensation for insulin resistance in male mice[J].Endocrinology,2016,157(3):1055-1070.
[11]Shen QU,Ting Z,Henry D.Effect of hepatic insulin expression on lipid metabolism in diabetic mice[J].J Diabetes,2016,8(3):314-323.
[12] Kobayashi J,Mabuchi H.Lipoprotein lipase and atherosclerosis[J]. Ann Clin Biochem,2015,52(6):632-637.
[13]Casanovas A,Parramon N,Llobera M,et al.Retroperitoneal white adipose tissue lipoprotein lipase activity is rapidly down-regulated in response to acute stress[J].J Lipid Res,2007,48(4):863-868.
[14]Bouvy LM,Heinaniemi M,John E,et al.Combinatorial regulation of lipoprotein lipase by microRNAs during mouse adipogenesis[J].RNA Biol,2014,11(1):76-91.
[15]Larsson M, Vorrsj? E, Talmud P,et al.Apolipoprotein C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets[J].J Biol Chem,2013,288(47):33997-34008.
[16]Surendran RP,Visser ME,Heemelaar S,et al.Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia[J].J Intern Med,2012,272(2):185-196.
[17]De CO,Fernando C,Maria JP,et al.Rare genetic variants with large effect on triglycerides in subjects with a clinical diagnosis of familial versus non-familial hypertriglyceridemia[J].J Clin Lipidol,2016,10(4):790-797.
[18]Kolovou GD,Kolovou V,Panagiotakos DB,et al.Study of common variants of the apolipoprotein E and lipoprotein lipase genes in patients with coronary heart disease and variable body mass index[J].Hormones (Athens),2015,14(3):376-382.
[19]Chi X, Britt EC, Shows HW,et al.ANGPTL8 promotes the ability of ANGPTL3 to bind and inhibit lipoprotein lipase[J].Mol Metab,2017,6(10):1137-1149.
[20]Chen Y,Wang X, Shen Z,et al.Effect of the beta-3 adrenergic receptor Trp64Arg and uncoupling protein 1-3826 A>G genotypes on lipid and apolipoprotein levels in overweight/obese and non-obese Chinese subjects[J].Lipids Health Dis,2015,14:34.
[21]Liu J,Zhang B,Li M,et al.Study on relationship between Trp64Arg polymorphism of β3-adrenergic receptor gene and obesity and blood lipids[J].Zhonghua Yi Xue Za Zhi,2015,95(20):1558-1562.
相似文献/References:
[1]彭彦人 郑华.甘油三酯与冠心病[J].心血管病学进展,2020,(10):1012.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.004]
PENG YanrenZHENG Hua.Triglycerides and Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2020,(9):1012.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.004]
[2]刘力黎 陈诚 张丽敏.血脂水平与心房颤动相关性研究进展[J].心血管病学进展,2021,(6):539.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.015]
LIU Lili,CHEN Cheng,ZHANG Limin.Serum Lipid Level and Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(9):539.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.015]
[3]唐琛 史宏志 韩红亚 刘晓丽 赵亦骢 王琛茜 张佳宜.应激性心肌病的研究进展[J].心血管病学进展,2024,(7):593.[doi:10.16806/j.cnki.issn.1004-3934.2024.07.005]
TANG Chen,SHI Hongzhi,HAN Hongya,et al.Stress-Induced Cardiomyopathy[J].Advances in Cardiovascular Diseases,2024,(9):593.[doi:10.16806/j.cnki.issn.1004-3934.2024.07.005]